Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 2/20 | 0.50 |
| ▸ | CYCS | P99999 | 3/20 | 0.49 |
| ▸ | TERT | O14746 | 3/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556430 | 1.00 | TOP1 (0.50) | TOP1CYCSTERTENPP2STAT3 | |
| SCHEMBL31296593 | 1.00 | TOP1 (0.50) | TOP1CYCSTERTENPP2STAT3 | |
| SCHEMBL29648445 | 0.98 | TERT (0.51) | TOP1CYCSTERTENPP2STAT3 | |
| SCHEMBL8865323 | 0.98 | TERT (0.51) | TOP1CYCSTERTENPP2STAT3 | |
| SCHEMBL30297908 | 0.98 | TERT (0.51) | TOP1CYCSTERTENPP2STAT3 | |
| SCHEMBL1640992 | 0.95 | TOP1 (0.54) | TOP1CYCSTERTENPP2STAT3 | |
| Temoporfin SCHEMBL6422 | 0.90 | TOP1 (0.43) | TOP1CYCSTERTENPP2STAT3 | |
| SCHEMBL5100886 | 0.90 | TOP1 (0.43) | TOP1CYCSTERTENPP2STAT3 | |
| SCHEMBL17651778 | 0.90 | TOP1 (0.43) | TOP1CYCSTERTENPP2STAT3 | |
| SCHEMBL17651811 | 0.90 | TOP1 (0.43) | TOP1CYCSTERTENPP2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023044436-A1 | AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THE PREPARATION THEREOF, AND METHODS FOR THE USE THEREOF | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2023-03-23 | — | — | WO | claimed |
| EP-1600766-B1 | ACTIVE OXYGEN SPECIES MEASURING DEVICE | YUASA MAKOTO (JP) | 2019-06-26 | — | — | EP | claimed |
| US-9867800-B2 | Method of quenching singlet and triplet excited states of pigments, such as porphyrin compounds, particularly protoporphyrin IX, with conjugated fused tricyclic compounds have electron withdrawing groups, to reduce generation of reactive oxygen species, particularly singlet oxygen | HALLSTAR INNOVATIONS CORP. (US) | 2018-01-16 | — | — | US | claimed |
| CN-106913533-A | The nanoparticulate carriers system for PDT based on poly- (DL PLGAs) | 拜欧利泰克投资二代公司 | 2017-07-04 | — | — | CN | claimed |
| US-20150164852-A1 | METHOD OF QUENCHING SINGLET AND TRIPLET EXCITED STATES OF PIGMENTS, SUCH AS PORPHYRIN COMPOUNDS, PARTICULARLY PROTOPORPHYRIN IX, WITH CONJUGATED FUSED TRICYCLIC COMPOUNDS HAVE ELECTRON WITHDRAWING GROUPS, TO REDUCE GENERATION OF REACTIVE OXYGEN SPECIES, PARTICULARLY SINGLET OXYGEN | HALLSTAR INNOVATIONS CORP. (US) | 2015-06-18 | — | — | US | claimed |
| WO-2014025370-A1 | TRICYCLIC ENERGY QUENCHER COMPOUNDS FOR REDUCING SINGLET OXYGEN GENERATION | HALLSTAR INNOVATIONS CORP. (US) | 2014-02-13 | — | — | WO | claimed |
| US-8298387-B2 | Reactive oxygen species measuring device | YUASA MAKOTO (JP) | 2012-10-30 | — | — | US | claimed |
| EP-1798600-B1 | Use of a porhine agent for reducing the potential of ghosting in an imaging member | XEROX CORP (US) | 2012-10-10 | — | — | EP | claimed |
| WO-2012000610-A1 | COMPLEXES WITH POLYSTYRENE SULFONATE | Universität des Saarlandes (DE) | 2012-01-05 | — | — | WO | claimed |
| US-20110275686-A1 | NANOPARTICLE CARRIER SYSTEMS BASED ON POLY(DL-LACTIC-CO-GLYCOLIC ACID) (PLGA) FOR PHOTODYNAMIC THERAPY (PDT) | BIOLITEC, INC. | 2011-11-10 | — | — | US | claimed |
| EP-0977592-A4 | METHOD FOR IMPROVED SELECTIVITY IN PHOTO-ACTIVATION OF MOLECULAR AGENTS | PHOTOGEN INC (US) | 2001-01-10 | — | — | EP | claimed |
| WO-2000071028-A1 | IMPROVED METHODS AND APPARATUS FOR MULTI-PHOTON PHOTO-ACTIVATION AND DETECTION OF MOLECULAR AGENTS | PHOTOGEN, INC. (US) | 2000-11-30 | — | — | WO | claimed |
| EP-1032321-A1 | METHOD FOR IMPROVED SELECTIVITY IN PHOTO-ACTIVATION AND DETECTION OF MOLECULAR DIAGNOSTIC AGENTS | Photogen, Inc. (US) | 2000-09-06 | — | — | EP | claimed |
| EP-1032321-A4 | METHOD FOR IMPROVED SELECTIVITY IN PHOTO-ACTIVATION AND DETECTION OF MOLECULAR DIAGNOSTIC AGENTS | PHOTOGEN INC (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0977592-A1 | METHOD FOR IMPROVED SELECTIVITY IN PHOTO-ACTIVATION OF MOLECULAR AGENTS | Photogen, Inc. (US) | 2000-02-09 | — | — | EP | claimed |
| US-5998597-A | THE TREATMENT OF A PARTICULAR VOLUME OF PLANT OR ANIMAL TISSUE COMPRISING THE STEPS OF TREATING THE PLANT OR ANIMAL TISSUE WITH AT LEAST ONE PHOTO-ACTIVE MOLECULAR AGENT. | PHOTOGEN, INC. (US) | 1999-12-07 | — | — | US | claimed |
| US-5832931-A | Method for improved selectivity in photo-activation and detection of molecular diagnostic agents | PHOTOGEN, INC. (US) | 1998-11-10 | — | — | US | claimed |
| US-5829448-A | ANTITUMOR | PHOTOGEN, INC. (US) | 1998-11-03 | — | — | US | claimed |
| WO-1998018398-A1 | METHOD FOR IMPROVED SELECTIVITY IN PHOTO-ACTIVATION AND DETECTION OF MOLECULAR DIAGNOSTIC AGENTS | PHOTOGEN, INC. (US) | 1998-05-07 | — | — | WO | claimed |
| WO-1998018399-A1 | METHOD FOR IMPROVED SELECTIVITY IN PHOTO-ACTIVATION OF MOLECULAR AGENTS | PHOTOGEN, INC. (US) | 1998-05-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164852-A1 | METHOD OF QUENCHING SINGLET AND TRIPLET EXCITED STATES OF PIGMENTS, SUCH AS PORPHYRIN COMPOUNDS, PARTICULARLY PROTOPORPHYRIN IX, WITH CONJUGATED FUSED TRICYCLIC COMPOUNDS HAVE ELECTRON WITHDRAWING GROUPS, TO REDUCE GENERATION OF REACTIVE OXYGEN SPECIES, PARTICULARLY SINGLET OXYGEN | NOX3, CBR3, CCR3 | TOP1 1886/4885CYCS 77/4885TERT 1768/4885 |
| US-20110275686-A1 | NANOPARTICLE CARRIER SYSTEMS BASED ON POLY(DL-LACTIC-CO-GLYCOLIC ACID) (PLGA) FOR PHOTODYNAMIC THERAPY (PDT) | MTHFD1, DLD, HPD | TOP1 1785/4885CYCS 3393/4885TERT 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.